DPP4 and acute pancreatitis: Once-weekly exenatide resulted in a nominal 9% relative reduction in major adverse cardiovascular events and a 14% relative reduction in all-cause mortality compared to placebo in T2DM with and without known cardiovascular disease [22], whereas dipeptidyl peptidase-4 inhibitors had no effect on cardiovascular risk outcomes but increased risks of acute pancreatitis and hypoglycemia [23].